A Phase 4 interventional study of Prograf and Tacrolimus Hexal in Pharmacokinetics Study in de Novo Kidney Transplantation, sponsored by Novartis Pharmaceuticals. Completed at 5 sites in Germany. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2019-06-17.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing tacrolimus in Graft vs Host Disease — 3 open to participants now, 4 under way, none of them phase 3. Tacrolimus · Graft vs Host Disease.
Among the 36 studies testing tacrolimus in Graft vs Host Disease, this one is the 5th largest by enrollment of the 32 interventional ones that give a count, is one of 3 that started in 2012, is one of 3 in phase 4, and was the 24th registered.
804 studies on the registry are indexed under Graft vs Host Disease; 149 are open to participants now.
Browse Graft vs Host Disease studies →3 of the 36 studies testing tacrolimus in Graft vs Host Disease are open now, in 1 country. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18–75
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages up to 26
City of Hope Medical Center · Sites in United States
Ages 18–80
By country, each count listing its studies:
Tacrolimus: first FDA approval 1994 (PROGRAF), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 103 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 42 (41%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 28 · Phase 3 4 · Phase 4 3
First in 2000; this study’s year is marked. 3 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 73 is above the median of 35 across 639 interventional studies indexed under Graft vs Host Disease.
Median enrollment 34 across the 32 interventional studies. Of the 32 that completed or were terminated, 15 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 36 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
12 studies in Graft vs Host Disease by Novartis: 2 open now, 4 under way, none of them phase 3. Of 8 finished, 7 (88%) have results posted.
Among the 12 studies in Graft vs Host Disease by Novartis, this one is the 6th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2012, is one of 5 in phase 4, and was the 1st registered.
Novartis’s Graft vs Host Disease studies by the year they started, since 2012.
1 of the studies testing tacrolimus in Graft vs Host Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05621759NYU Langone HealthCyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD | 2027-01-30 |
Add it to your calendar (.ics) → With an account.
Among the 36 studies testing tacrolimus in Graft vs Host Disease, from their registry updates:
Among Novartis’s 12 in Graft vs Host Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to investigate if Tacrolimus Hexal® has similar pharmacokinetic properties compared to Prograf® in de novo renal transplant patients and whether the comparable exposure resulted in similar renal function.
In Phase II of this study there was a high patient drop-out rate and an associated long recruitment timespan. Eighty-one patients were recruited to Phase I and only 45 of the required 54 patients were available for PK analysis. To complete Phase II, 245 (in addition to 81) patients were to be required to achieve calculated sample size. Therefore the protocol was amended to stop recruitment and analyze Phase I patient data of CERL080ADE27 (PK-Phase I). Patients that were still ongoing were scheduled for an end of study (EOS) visit. During this visit patients were informed by the investigator about the end of study and advised about further treatment course.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
primary or sec. kidney transplanted patiens, written consent, cold ischemia \< 24 h
Exclusion:
multi organ, immunological risc pts., PRA >20%, Antibodys against HLA-type of donor organ, against Tacro or MMF,
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Control therapy: one capsule containing 0.5 mg, 1mg or 5mg Prograf®, one tablet containing 180mg or 360mg Myfortic®, corticosteroids and one vial containing 20mg lyophilisate Simulect®
Drug: Prograf
Investigational therapy: one capsule containing 0.5mg, 1mg or 5mg Tacrolimus Hexal®, one tablet containing 180mg or 360mg Myfortic®, corticosteroids and one vial containing 20mg lyophilisate Simulect®
Drug: Tacrolimus Hexal
Prograf® capsules were supplied as capsules of 0.5 mg, 1 mg and 1.5 mg dose strengths.
Tacrolimus Hexal® capsules were supplied to the investigators at dose strengths of 0.5 mg, 1 mg and 1.5 mg.
ANCOVA Model for Change in Nankivell GFR (mL/Min) at Month 6, Without Replacement of Missing Values (Full Analysis Set)
Change in Nankivell glomerular filtration rate (GFR) from baseline to 6 months Glomerular Filtration Rate (GFR): The GFR is the best clinical estimate of renal function in health and disease, and correlates well with the clinical severity of renal function disturbances. Several studies have shown that in patients with progressive renal disease, GFR declines or reciprocal serum creatinine levels elevate linearly over time in a predictable manner. With the help of the serum creatinine values, the GFR was calculated via Nankivell formula.
Time frame: baseline to month 6
ANOVA for Dose-normalized Tacrolimus 12-h-AUC (h/103*L) at Month 1
Compares the PK of Tacrolimus Hexal® assessed by the ratio of the AUC0-12h over one month period post transplantation vs. Prograf® in renal transplant patients
Time frame: end of month 1
The Incidence of Biopsy-proven Acute Rejection (BPAR), Graft Loss and Death Until Month 12 (Full Analysis Set) (Full Analysis Set)
The key secondary objective was to assess the incidence of individual endpoints BPAR, graft loss and death until month 6 post-transplantation.
Time frame: baseline to month 12
ANCOVA Model for Change in CKD-EPI GFR (Chronic Kidney Disease Epidemiology Collaboration Glomerular Filtration Rate) at Month 6 Post-transplantation
ANCOVA model for change in CKD-EPI Glomerular Filtration Rate (GFR)\[ml/min\] without replacement of missing values
Time frame: baseline to Month 6
ANCOVA Model for Change in MDRD GFR (ml/Min) at Month 6, Without Replacement of Missing Values
MDRD GFR
Time frame: least square (LS) mean change from baseline to Month 6
ANCOVA Model for Change in Cockcroft-Gault GFR (ml/Min) at Month 6, Without Replacement of Missing Values
change in Cockcroft-Gault GFR
Time frame: least square (LS) mean change from baseline to Month 6
81 patients were randomized, but only 73 were assigned drug. 1 patient who was excluded from efficacy analyses, was randomized to Prograf but did not receive treatment but kept for safety reporting. 74 patients were used for safety analysis while only 73 were available for efficacy analysis
| Milestone | Tacrolimus Hexal® | Prograf® |
|---|---|---|
| Started | 35 | 38 |
| Completed | 24 | 26 |
| Not completed | 11 | 12 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Withdrawal by subject | 8 | 7 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Graft loss | 0 | 1 |
| Withdrew: Surgical problems during nephrectomy | 2 | 2 |
Change in Nankivell glomerular filtration rate (GFR) from baseline to 6 months Glomerular Filtration Rate (GFR): The GFR is the best clinical estimate of renal function in health and disease, and correlates well with the clinical severity of renal function disturbances. Several studies have shown that in patients with progressive renal disease, GFR declines or reciprocal serum creatinine levels elevate linearly over time in a predictable manner. With the help of the serum creatinine values, the GFR was calculated via Nankivell formula.
| mL/min | Tacrolimus Hexal® | Prograf® |
|---|---|---|
| ANCOVA Model for Change in Nankivell GFR (mL/Min) at Month 6, Without Replacement of Missing Values (Full Analysis Set) | 47.65 ± 20.24 | 38.60 ± 18.83 |
The key secondary objective was to assess the incidence of individual endpoints BPAR, graft loss and death until month 6 post-transplantation.
| Incidences | Tacrolimus Hexal® | Prograf® |
|---|---|---|
| Biopsy proven acute rejection (BPAR) | 2 (0.70 to 19.16) | 3 (1.66 to 21.38) |
| Graft loss | 0 (0.00 to 10.00) | 1 (0.07 to 13.81) |
| Death | 0 (0.00 to 10.00) | 1 (0.07 to 13.81) |
| Composite: BPAR, graft loss or death | 2 (0.70 to 19.16) | 4 (2.94 to 24.80) |
ANCOVA model for change in CKD-EPI Glomerular Filtration Rate (GFR)\[ml/min\] without replacement of missing values
| mL/min | Tacrolimus Hexal® | Prograf® |
|---|---|---|
| ANCOVA Model for Change in CKD-EPI GFR (Chronic Kidney Disease Epidemiology Collaboration Glomerular Filtration Rate) at Month 6 Post-transplantation | 48.33 ± 3.84 | 39.77 ± 4.61 |
Compares the PK of Tacrolimus Hexal® assessed by the ratio of the AUC0-12h over one month period post transplantation vs. Prograf® in renal transplant patients
| h/10^3*L | Tacrolimus Hexal® | Prograf® |
|---|---|---|
| Adjusted, log-transformed Estimates (ANOVA) | 2.944 (2.783 to 3.105) | 3.020 (2.811 to 3.228) |
| Adjusted, back-transformed Estimates (ANOVA) | 18.991 (16.163 to 22.314) | 20.484 (16.630 to 25.231) |
MDRD GFR
| (ml/min) | Tacrolimus Hexal® | Prograf® |
|---|---|---|
| ANCOVA Model for Change in MDRD GFR (ml/Min) at Month 6, Without Replacement of Missing Values | 46.20 (37.62 to 54.79) | 38.52 (28.64 to 48.41) |
change in Cockcroft-Gault GFR
| (ml/min) | Tacrolimus Hexal® | Prograf® |
|---|---|---|
| ANCOVA Model for Change in Cockcroft-Gault GFR (ml/Min) at Month 6, Without Replacement of Missing Values | 60.45 (52.48 to 68.41) | 46.45 (36.89 to 56.02) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tacrolimus Hexal | — | 19/35 (54.3%) | 34/35 (97.1%) |
| Prograf | — | 17/39 (43.6%) | 38/39 (97.4%) |
| Event | Tacrolimus Hexal | Prograf |
|---|---|---|
| URINARY TRACT INFECTIONInfections and infestations | 4/35 | 4/39 |
| COMPLICATIONS OF TRANSPLANTED KIDNEYInjury, poisoning and procedural complications | 4/35 | 3/39 |
| BLOOD CREATININE INCREASEDInvestigations | 4/35 | 1/39 |
| DIARRHOEAGastrointestinal disorders | 3/35 | 0/39 |
| ACUTE KIDNEY INJURYRenal and urinary disorders | 3/35 | 0/39 |
| PROTEINURIARenal and urinary disorders | 3/35 | 0/39 |
| KIDNEY TRANSPLANT REJECTIONImmune system disorders | 2/35 | 2/39 |
| UROSEPSISInfections and infestations | 2/35 | 0/39 |
| INCISIONAL HERNIAInjury, poisoning and procedural complications | 2/35 | 0/39 |
| FOCAL SEGMENTAL GLOMERULOSCLEROSISRenal and urinary disorders | 2/35 | 0/39 |
| Event | Tacrolimus Hexal | Prograf |
|---|---|---|
| HYPERTENSIONVascular disorders | 12/35 | 20/39 |
| WOUND COMPLICATIONInjury, poisoning and procedural complications | 16/35 | 19/39 |
| URINARY TRACT INFECTIONInfections and infestations | 6/35 | 16/39 |
| COMPLICATIONS OF TRANSPLANTED KIDNEYInjury, poisoning and procedural complications | 5/35 | 11/39 |
| HYPERKALAEMIAMetabolism and nutrition disorders | 9/35 | 9/39 |
| HYPERURICAEMIAMetabolism and nutrition disorders | 3/35 | 9/39 |
| ANAEMIABlood and lymphatic system disorders | 4/35 | 7/39 |
| LEUKOPENIABlood and lymphatic system disorders | 3/35 | 7/39 |
| OEDEMA PERIPHERALGeneral disorders | 3/35 | 7/39 |
| HYPOMAGNESAEMIAMetabolism and nutrition disorders | 5/35 | 7/39 |
The Full Analysis Set (FAS) consisted of all patients in whom study treatment was assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment they were assigned to at randomization
| Age, Continuous(years) | Tacrolimus Hexal® | Prograf® | Total |
|---|---|---|---|
| Mean | 47.9 ± 9.9 | 47.2 ± 11.8 | 47.5 ± 10.8 |
| Sex: Female, Male(Participants) | Tacrolimus Hexal® | Prograf® | Total |
|---|---|---|---|
| Female | 6 | 9 | 15 |
| Male | 29 | 29 | 58 |
Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
No publications or documents are linked to this record.
Ran from Oct 2012 to primary completion in Aug 2015, 34 months.
Results were first posted in Jun 2019, 3 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tacrolimus